Long-term safety of droxidopa in patients with symptomatic neurogenic orthostatic hypotension

Stuart Isaacson, Steven Vernino, Adam Ziemann, Gerald J. Rowse, Uwa Kalu, William B. White

Research output: Contribution to journalArticlepeer-review

21 Scopus citations


The long-term safety of droxidopa for the treatment of symptomatic neurogenic orthostatic hypotension in patients with Parkinson disease, pure autonomic failure, multiple system atrophy, or nondiabetic autonomic neuropathy was evaluated in a phase 3, multinational, open-label study in patients who previously participated in a double-blind, placebo-controlled clinical trial of droxidopa. A total of 350 patients received droxidopa 100 to 600 mg three times daily. Mean duration of droxidopa exposure was 363 days (range, 2–1133 days). Rates of serious adverse events (AEs), cardiac-related AEs, and supine hypertension were 24%, 5%, and 5%, respectively. Most AEs, including those of a cardiovascular nature, were not attributed by investigators to droxidopa. In this large cohort of patients with neurogenic orthostatic hypotension, droxidopa was well tolerated during long-term use.

Original languageEnglish (US)
Pages (from-to)755-762
Number of pages8
JournalJournal of the American Society of Hypertension
Issue number10
StatePublished - Oct 1 2016


  • Supine hypertension

ASJC Scopus subject areas

  • Internal Medicine
  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Long-term safety of droxidopa in patients with symptomatic neurogenic orthostatic hypotension'. Together they form a unique fingerprint.

Cite this